Articles
Media
Publications
Conferences
CME/CE
Resources
Subscribe

Spotlight -

ZEISS Clinical Cases|

Heidelberg Engineering: Enhancing the Patient Journey

Opinion|Videos|February 7, 2025

Safety Profile of New Therapies

Author(s)John Kitchens, MD, Richard Gale, PhD, MEd, BSc, MBChB, FRCP, FRCOphth, Michael W. Stewart, MD

Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.

Episodes in this series

3 experts are featured in this series.

EP. 1 Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

3 experts are featured in this series.

EP. 2 Advantages of the Molecular Structure of Aflibercept

3 experts are featured in this series.

EP. 3 Treat-and-Extend Strategy With Aflibercept

3 experts are featured in this series.

EP. 4 Assessing New Therapies for Retinal Diseases

3 experts are featured in this series.

EP. 5 Significance of the Higher Molar Dose of Aflibercept 8 mg

3 experts are featured in this series.

EP. 6 Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

3 experts are featured in this series.

EP. 7 Patient Selection for Aflibercept 8 mg

3 experts are featured in this series.

EP. 8 Faricimab Molecular Design and Role of Ang-2

3 experts are featured in this series.

EP. 9 Outcomes with Raricimab and Choosing Between the New Therapies

3 experts are featured in this series.

EP. 10 Safety Profile of New Therapies

3 experts are featured in this series.

EP. 11 Perspectives on the Usefulness of Real-world Data

3 experts are featured in this series.

EP. 12 Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

3 experts are featured in this series.

EP. 13 Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Video content above is prompted by the following:

Based on the clinical trial data, how do you view the safety profiles of faricimab and aflibercept 8 mg?
Does the long-term safety profile of aflibercept 2 mg increase your confidence in the safety of aflibercept 8 mg?
Does the increased volume of aflibercept 8 mg raise concerns about the potential for elevated intraocular pressure? How do you evaluate and address this in clinical practice?

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Content

(Image credit: AdobeStock/doraclub) FLORetina 2025: Bridging global gaps in ROP care

FLORetina 2025: Bridging global gaps in ROP care

ByRajvardhan Azad, MD, FRCSed, FAMS, FAAPPO, FAICO,Sheryl Stevenson,Kassi Filkins

December 4th 2025

FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years

ByLynda Charters

December 4th 2025

FLORetina 2025: Fibrosis, a limiting factor in visual acuity outcomes in neovascular AMD

ByLynda Charters

December 4th 2025

(Image credit: AdobeStock/Jess rodriguez)

FLORetina 2025: Artificial intelligence at the frontlines of ROP care

ByJ. Peter Campbell, MD, MPH,Sheryl Stevenson,Kassi Filkins

December 4th 2025

Celltrion’s EYLEA-referencing biosimilar, EYDENZELT, receives Canadian approval

ByMartin David Harp

December 2nd 2025

Latest CME

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

Arshad M. Khanani, MD, MA, FASRS; Carl J. Danzig, MD, FASRS; Jennifer I. Lim, MD, FARVO

(COPE Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

(COPE Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Mitch Ibach, OD, FAAO; Jessica Steen, OD, FAAO

$(CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery$

(CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

Zeba A. Syed, MD

(CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

Laxmi V. Devisetty, MD; Rodney P. Coe, MD, MS; Majda Hadziahmetovic, MD; Xiao Yi (Ellie) Zhou, MD

(CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

Rahul Tonk, MD, MBA

(COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

David S. Liao, MD, PhD; Chang Sup Lee, MD; Douglas Matsunaga, MD; Daniel Su, MD

20th Annual Controversies in Modern Eye Care

In-Person Event

20th Annual Controversies in Modern Eye Care

April 19, 2026

(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

David M. Brown, MD, FACS; Dilraj S. Grewal, MD

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Deborah Ristvedt, DO; Melissa Tawa, OD, FAAO

(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

Marjan Farid, MD; John Hovanesian, MD; Beeran Meghpara, MD

(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

Tanner Ferguson, MD; Taj Nasser, MD, FWCRS

(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

David A. Eichenbaum, MD

(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

Nathan C. Steinle, MD

(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

Tanner Ferguson, MD; Taj Nasser, MD, FWCRS

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; John Hovanesian, MD, FACS

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

SriniVas Sadda, MD, FARVO; Nathan Steinle, MD

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Mark Schaeffer, OD, FAAO; Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO, FAAOMS; Selina R. McGee, OD, FAAO

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

Deborah Ristvedt, DO; Melissa Tawa, OD, FAAO

Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis | Houston, TX

In-Person Event

Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis | Houston, TX

December 4, 2025

The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

December 9, 2025

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

Jacqueline Theis, OD, FAAO; Cecelia Koetting, OD, FAAO, DipABO; Melissa Barnett, OD, FAAO, FSLS, FBCLA

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention

Jacqueline Theis, OD, FAAO; Cecelia Koetting, OD, FAAO, DipABO; Melissa Barnett, OD, FAAO, FSLS, FBCLA

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Mitch Ibach, OD, FAAO; Jessica Steen, OD, FAAO

Rapid Reviews in Retina™: Emerging Updates from Fall 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME

Rapid Reviews in Retina™: Emerging Updates from Fall 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME

Diana V. Do, MD; Michael W. Stewart, MD; Paolo Lanzetta, MD; Dilraj Grewal, MD

EnVision Summit

In-Person Event

EnVision Summit

February 13-16, 2026

(CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

David S. Liao, MD, PhD; Chang Sup Lee, MD; Douglas Matsunaga, MD; Daniel Su, MD

Practical Approaches to Modern Dry Eye Treatment and Management

Practical Approaches to Modern Dry Eye Treatment and Management

Marc R. Bloomenstein, OD, FAAO; Cory J. Lappin, OD, MS, FAAO; Selina R. McGee, OD, FAAO

(CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

Adrienne W. Scott, MD, FASRS; Justine Cheng, MD; Hong-Uyen Hua, MD; Sherrol A. Reynolds OD, FAAO, FNAP

(COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

Laxmi V. Devisetty, MD; Rodney P. Coe, MD, MS; Majda Hadziahmetovic, MD; Xiao Yi (Ellie) Zhou, MD

(CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

Rachel Simpson, MD; James Murphy, MD; Mary Qiu, MD; Jessica Steen, OD, FAAO

(CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

Sara T. Wester, MD, FACS; Cecelia Koetting, OD; Sophie Liao, MD; Jennifer Murdock, MD

(COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

Rahul Tonk, MD, MBA

$(COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery$

(COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

Zeba A. Syed, MD

(COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

Adrienne W. Scott, MD, FASRS; Justine Cheng, MD; Hong-Uyen Hua, MD; Sherrol A. Reynolds OD, FAAO, FNAP

(COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

Sara T. Wester, MD, FACS; Cecelia Koetting, OD; Sophie Liao, MD; Jennifer Murdock, MD

(COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

Rachel Simpson, MD; James Murphy, MD; Mary Qiu, MD; Jessica Steen, OD, FAAO

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Yasha Modi, MD; Carolyn Majcher, OD, FAAO, FORS

(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Yasha Modi, MD; Carolyn Majcher, OD, FAAO, FORS

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

David M. Brown, MD, FACS; Dilraj S. Grewal, MD

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

Lejla Vajzovic, MD, FASRS; Ramiro Maldonado, MD

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

Lejla Vajzovic, MD, FASRS; Ramiro Maldonado, MD

(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

Veeral Sheth, MD, MBA, FASRS, FACS; Mark R. Barakat, MD, FASRS; Geeta Lalwani, MD; Xiao Yi Zhou, MD

(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

Veeral Sheth, MD, MBA, FASRS, FACS; Mark R. Barakat, MD, FASRS; Geeta Lalwani, MD; Xiao Yi Zhou, MD

Collaborative Care Symposium

Collaborative Care Symposium

May 2-3, 2026

(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

Melissa Barnett, OD, FAAO, FSLS, FBCLA; Cecelia Koetting, OD, FAAO, DipABO; Quan Đông Nguyễn, MD, MSc; Jennifer Li, MD

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

Melissa Barnett, OD, FAAO, FSLS, FBCLA; Cecelia Koetting, OD, FAAO, DipABO; Quan Đông Nguyễn, MD, MSc; Jennifer Li, MD

(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

Marjan Farid, MD; John Hovanesian, MD; Beeran Meghpara, MD

(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

David A. Eichenbaum, MD

(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

Nathan C. Steinle, MD

Trending on Ophthalmology Times Europe

FLORetina 2025: Artificial intelligence at the frontlines of ROP care

FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years

How Digital Workflow Boosted my Confidence and Elevated Premium Patient Rates in Cataract Surgery

FLORetina 2025: Weight and PMA drive foveal maturation in preterm infants

FLORetina 2025: Fibrosis, a limiting factor in visual acuity outcomes in neovascular AMD

© 2025 MJH Life Sciences^®

All rights reserved.